You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PAR-24-157: Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)

    Release Date: 02-29-2024Open Date: 03-05-2024 Due Dates: Multiple Close Date: 01-06-2027

    Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), works to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Translation is the process of turning observations in the ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. DHA244-D003: Advanced Information Technology to Improve Mobility, Interoperability, and Survivability of Expeditionary Medical Command, Control, Communications, and Computers (Direct to Phase II)

    Release Date: 10-03-2023Open Date: 03-26-2024Due Date: 03-31-2025Close Date: 05-13-2025

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Combat Casualty Care OBJECTIVE: This topic is intended for technology proven ready to move directly into Phase II and is accepting Direct to Phase II proposals only. Develop expeditionary and interoperable information technology (IT) to enable health care delivery (HCD), medical command and control (MEDC2), medical logistics (MEDLOG), and patient movemen ...

    SBIRPhase I/Phase IIDepartment of DefenseDefense Health Agency
  3. PAS-22-197: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

    Release Date: 06-21-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-06-2025

    Recommendations and milestones for Alzheimer's disease (AD) and AD-related dementias (ADRD) research from the National Alzheimer’s Project Act and, the 2015, 2018, 2019, and 2021 Alzheimer's Disease Research Summits present a wide range of research and development proposals which, if pursued, have the potential to reduce the human burden and healthcare costs associated with AD/ADRD. As part of ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. PAS-22-196: Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

    Release Date: 06-21-2022Open Date: 12-05-2022 Due Dates: Multiple Close Date: 09-08-2025

    Recommendations and milestones for Alzheimer's disease (AD) and AD-related dementias (ADRD) research from the National Alzheimer’s Project Act and the 2015, 2018, 2019, and 2021 Alzheimer's Disease Research Summits present a wide range of research and development proposals which, if pursued, have the potential to reduce the human burden and healthcare costs associated with AD/ADRD. As part of t ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-24-098: Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

    Release Date: 01-22-2024Open Date: 02-22-2024 Due Dates: Multiple Close Date: 06-26-2026

    Background A biomarker is a defined characteristic that is measured as an indicator of a normal biological process, pathogenic process, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities are diverse, and can include ‘omics, imaging, behavioral, digital and physiologic endpoints. Because the measurement of the biomarker is integral to defining ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. A244-016: Autonomous Optical Sensors

    Release Date: 10-03-2023Open Date: 03-04-2024Due Date: 03-31-2025Close Date: 04-22-2024

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Integrated Sensing and Cyber; Trusted AI and Autonomy; Integrated Network Systems-of-Systems OBJECTIVE: This project aims to develop a portable optical sensor that can capture high-quality real-time imagery data during missile tests. The sensor will be positioned near a missile launcher during the launch or near the target to analyze the terminal phase of t ...

    SBIRPhase I/Phase IIDepartment of DefenseArmy
  7. PAR-21-282: Blueprint Medtech: Small Business Translator (U44- Clinical Trial Optional)

    Release Date: 08-20-2021Open Date: 09-20-2021 Due Dates: Multiple Close Date: 06-21-2024

    Blueprint MedTech The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). Innovators developing groundbreaking medical ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PAR-21-233: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 04-23-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. PAR-21-162: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 03-29-2021Open Date: 07-10-2021 Due Dates: Multiple Close Date: 04-06-2024

    A. Overview Recent advances in biology offer unprecedented opportunities to discover new treatments for nervous system disorders. Biotherapeutic development, however, has inherent complexities with regards to characterization, manufacturing, delivery, and administration. Many academic laboratories and small business enterprises don’t have the full scope of expertise and resources available; thi ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. PAR-24-063: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

    Release Date: 11-01-2023Open Date: 01-09-2024 Due Dates: Multiple Close Date: 08-19-2026

    Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervous system disorders. However, before a new chemical entity can be tested in a clinical setting, it must undergo a process of chemical optimization to improve potency, selectivity, and drug-like properties, followed by pre-clinical safety testing to meet the standards set by the Food and Drug Admin ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government